Opinion on medicine for use outside EU: Dengue Tetravalent Vaccine (Live, Attenuated) Takeda, Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated,Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated,Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated,Dengue virus, serotype 2, live, attenuated, Dengue, 13/10/2022 Positive opinion

Third workshop between notified bodies and expert panels , Online, from 4 December 2025, 17:30 (CET) to 4 December 2025, 18:30 (CET)

Human medicines European public assessment report (EPAR): Velmetia, sitagliptin,metformin, Date of authorisation: 16/07/2008, Revision: 40, Status: Authorised

Agenda - HMA/EMA Annual Data Forum 2025

Human medicines European public assessment report (EPAR): Zinplava, bezlotoxumab, Date of authorisation: 18/01/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Efficib, sitagliptin,metformin, Date of authorisation: 15/07/2008, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Tesavel, sitagliptin, Date of authorisation: 10/01/2008, Revision: 29, Status: Authorised

Clinical investigation of medicinal products in the treatment of Parkinson's disease - Scientific guideline

Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease

Minutes - Management Board meeting: 2 October 2025